[go: up one dir, main page]

Flores-Romo et al., 1995 - Google Patents

Detoxified venom from Crotalus durissus terrificus is devoid of cytotoxic activity and induces mitogenesis

Flores-Romo et al., 1995

Document ID
350535730477658899
Author
Flores-Romo L
Heneine L
Heneine I
Publication year
Publication venue
Immunopharmacology and immunotoxicology

External Links

Snippet

The venom from the snake Crotalus durrissus terrificus was detoxified by stepwise incorporation of stable cationic iodine. The venoid, in a dosage equivalent to 100 LD50 of the letal venom, was injected in mice without lethal exits. The native venom (NAT), or its …
Continue reading at www.tandfonline.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A61K47/48261—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the peptide or protein in the drug conjugate being a toxin or a lectin, e.g. clostridial toxins or Pseudomonas exotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/30—Macromolecular compounds
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin, zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Similar Documents

Publication Publication Date Title
ES2220800T3 (en) CHLORELLA PREPARATIONS THAT SHOW IMMUNOMODULATING PROPERTIES.
Ellouz et al. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives
DE69736709T2 (en) MANY DTP POLIO VACCINES
Clissa et al. Toxicity and immunogenicity of Crotalus durissus terrificus venom treated with different doses of gamma rays
Lightowlers Vaccines against cysticercosis and hydatidosis: foundations in taeniid cestode immunology
EP0462534A2 (en) Acellular anti-pertussis vaccines
Baral et al. Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine
CN102238960A (en) Process for production of vaccines
Aguiyi et al. Studies on possible protection against snake venom using Mucuna pruriens protein immunization
ULLAH et al. Exotoxic substances produced by Edwardsiella tarda
Gao et al. A novel vaccine formulation candidate based on lipooligosaccharides and pertussis toxin against Bordetella pertussis
Baldwin Immunity to transplanted tumour: the effect of tumour extracts on the growth of homologous tumours in rats
Flores-Romo et al. Detoxified venom from Crotalus durissus terrificus is devoid of cytotoxic activity and induces mitogenesis
GB2140689A (en) Treating digestive ulcers using dna
Bergdoll Immunization of rhesus monkeys with enterotoxoid B
Flores-Romo et al. England, and “Department of General Pathology, Institute of Biological
CA2128212A1 (en) Detoxified lps-cholera toxin conjugate vaccine for prevention of cholera
Mohamed et al. Reactogenicity and safety assessment of an attenuated nanovaccine against scorpion envenomation: Preclinical study
Lopez-Merino et al. Immunization by an insoluble fraction extracted from Brucella melitensis: immunological and chemical characterization of the active substances
Guerranti et al. Characterization of the factor responsible for the antisnake activity of Mucuna pruriens seeds
Heneine et al. Stepwise iodination. A general procedure for detoxification of proteins suitable for vaccine development and antiserum production
KR100267746B1 (en) Oral immunological preparation containing egg-yolk antibodies, for prevention and treatment of porcine diarrhea caused by enterotoxigenic escherichia coli
Kubelkova et al. A SHORT HISTORY OF IMUREGEN-AN ORIGINAL TISSUE EXTRACT.
Mond et al. Thymus-derived cell (T cell) activation by heterologous antigens as a replacement of specific immune T cells in the transfer of the secondary response to sheep erythrocytes
Khiav et al. A simple method for purification of epsilon toxin of Clostridium perfringens type D for serum neutralization assay